NCT07073469View on ClinicalTrials.gov

Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

November 1, 2027

Conditions
Stroke Ischemic
Interventions
DRUG

Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)

Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)

OTHER

Standard medical treatment

Standard medical treatment according to local guidelines

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER